Literature DB >> 1902635

Defective candidacidal activity of alveolar macrophages and peripheral blood monocytes from patients with chronic obstructive pulmonary disease.

A Vecchiarelli1, M Dottorini, M Puliti, T Todisco, E Cenci, F Bistoni.   

Abstract

We investigated the in vitro candidacidal activity of alveolar macrophages (AM) and peripheral blood monocytes (PBM) from normal subjects or from patients with chronic obstructive pulmonary disease (COPD) displaying defective skin test delayed-type hypersensitivity (DTH) reactivity to seven antigens including Candida albicans. The results showed that cells from patients with COPD were significantly less effective than cells from control subjects in the killing of C. albicans. To explore whether the observed functional impairment could be reversed, interferon-gamma (IFN-gamma) was added to AM and PBM from patients with COPD, alone or in the presence of lipopolysaccharide (LPS) as a suboptimal stimulus. The cells were cultured for 24 h and then assayed for anti-Candida activity. After IFN-gamma treatment, the fungicidal activity of cells from patients with COPD was comparable to that of unstimulated AM or PBM from healthy donors. Treatment with IFN-gamma plus LPS resulted in a further enhancement in the killing of C. albicans. To gain more insight into the mechanisms involved in the modulation of killing, we evaluated the possible stimulating activity of IFN-gamma plus LPS treatment on the secretion of tumor necrosis factor (TNF) and interleukin-1 (IL-1), two cytokines produced by activated macrophages and capable of stimulating natural effectors. The results showed that IFN-gamma plus LPS can indeed stimulate TNF and IL-1 secretion by AM and PBM from patients with COPD. Therefore, a precise role can reasonably be ascribed to these soluble factors in the observed augmentation of candidacidal activity as ascertained by treatment with IFN-gamma plus LPS.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902635     DOI: 10.1164/ajrccm/143.5_Pt_1.1049

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  8 in total

1.  Airways inflammation in subjects with chronic bronchitis who have never smoked.

Authors:  M Lusuardi; A Capelli; C G Cerutti; E L Spada; C F Donner
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

2.  Pulmonary immunity to Pseudomonas aeruginosa in intestinally immunized rats roles of alveolar macrophages, tumor necrosis factor alpha, and interleukin-1 alpha.

Authors:  A Buret; M L Dunkley; G Pang; R L Clancy; A W Cripps
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

3.  Differential susceptibility of yeast and hyphal forms of Candida albicans to macrophage-derived nitrogen-containing compounds.

Authors:  E Blasi; L Pitzurra; M Puliti; A R Chimienti; R Mazzolla; R Barluzzi; F Bistoni
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

4.  The Candida albicans phospholipomannan induces in vitro production of tumour necrosis factor-alpha from human and murine macrophages.

Authors:  T Jouault; A Bernigaud; G Lepage; P A Trinel; D Poulain
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

5.  Interactions of P 1507, a new antioxidant agent, with phagocyte functions.

Authors:  F Meloni; P Ballabio; G Leo; M Gorrini; S Manzardo; G Coppi; M Luisetti
Journal:  Agents Actions       Date:  1994-11

Review 6.  Dysregulated Functions of Lung Macrophage Populations in COPD.

Authors:  Theodore S Kapellos; Kevin Bassler; Anna C Aschenbrenner; Wataru Fujii; Joachim L Schultze
Journal:  J Immunol Res       Date:  2018-02-18       Impact factor: 4.818

Review 7.  Lung Macrophage Phenotypes and Functional Responses: Role in the Pathogenesis of COPD.

Authors:  Kei Yamasaki; Stephan F van Eeden
Journal:  Int J Mol Sci       Date:  2018-02-15       Impact factor: 5.923

Review 8.  Lung Macrophage Functional Properties in Chronic Obstructive Pulmonary Disease.

Authors:  Kentaro Akata; Stephan F van Eeden
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.